178 related articles for article (PubMed ID: 23084634)
1. Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder.
Gonzalez-Roibon ND; Chaux A; Al-Hussain T; Osunkoya AO; Bezerra SM; Hicks J; Epstein JI; Netto GJ
Hum Pathol; 2013 Apr; 44(4):612-22. PubMed ID: 23084634
[TBL] [Abstract][Full Text] [Related]
2. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
Sun CH; Chang YH; Pan CC
Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma.
Munari E; Fujita K; Faraj S; Chaux A; Gonzalez-Roibon N; Hicks J; Meeker A; Nonomura N; Netto GJ
Hum Pathol; 2013 Dec; 44(12):2668-76. PubMed ID: 24074531
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
5. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.
Fahmy M; Mansure JJ; Brimo F; Yafi FA; Segal R; Althunayan A; Hicks J; Meeker A; Netto G; Kassouf W
Hum Pathol; 2013 Sep; 44(9):1766-72. PubMed ID: 23623586
[TBL] [Abstract][Full Text] [Related]
6. High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection.
Chaux A; Compérat E; Varinot J; Hicks J; Lecksell K; Solus J; Netto GJ
Urology; 2013 Jan; 81(1):116-22. PubMed ID: 23273076
[TBL] [Abstract][Full Text] [Related]
7. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
[TBL] [Abstract][Full Text] [Related]
8. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy.
Schultz L; Albadine R; Hicks J; Jadallah S; DeMarzo AM; Chen YB; Nielsen ME; Gonzalgo ML; Sidransky D; Schoenberg M; Netto GJ
Cancer; 2010 Dec; 116(23):5517-26. PubMed ID: 20939013
[TBL] [Abstract][Full Text] [Related]
9. Alterations of mTOR and PTEN protein expression in schistosomal squamous cell carcinoma and urothelial carcinoma.
Makboul R; Refaiy A; Abdelkawi IF; Hameed DA; Elderwy AA; Shalaby MM; Merseburger AS; Hussein MR
Pathol Res Pract; 2016 May; 212(5):385-92. PubMed ID: 26916953
[TBL] [Abstract][Full Text] [Related]
10. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
Seront E; Pinto A; Bouzin C; Bertrand L; Machiels JP; Feron O
Br J Cancer; 2013 Sep; 109(6):1586-92. PubMed ID: 23989949
[TBL] [Abstract][Full Text] [Related]
11. Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.
Qian CN; Furge KA; Knol J; Huang D; Chen J; Dykema KJ; Kort EJ; Massie A; Khoo SK; Vanden Beldt K; Resau JH; Anema J; Kahnoski RJ; Morreau H; Camparo P; Comperat E; Sibony M; Denoux Y; Molinie V; Vieillefond A; Eng C; Williams BO; Teh BT
Cancer Res; 2009 Nov; 69(21):8256-64. PubMed ID: 19843858
[TBL] [Abstract][Full Text] [Related]
12. Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas.
Chaux A; Schultz L; Albadine R; Hicks J; Kim JJ; Allaf ME; Carducci MA; Rodriguez R; Hammers HJ; Argani P; Reuter VE; Netto GJ
Hum Pathol; 2012 Dec; 43(12):2129-37. PubMed ID: 22542128
[TBL] [Abstract][Full Text] [Related]
13. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
[TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis.
Yang J; Liao D; Wang Z; Liu F; Wu G
J Surg Res; 2011 Jun; 168(1):97-102. PubMed ID: 20036387
[TBL] [Abstract][Full Text] [Related]
15. Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.
Kim HS; Kim GY; Lim SJ; Kim YW
Pathobiology; 2012; 79(2):84-93. PubMed ID: 22286903
[TBL] [Abstract][Full Text] [Related]
16. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
Costa C; Pereira S; Lima L; Peixoto A; Fernandes E; Neves D; Neves M; Gaiteiro C; Tavares A; Gil da Costa RM; Cruz R; Amaro T; Oliveira PA; Ferreira JA; Santos LL
PLoS One; 2015; 10(11):e0141253. PubMed ID: 26569621
[TBL] [Abstract][Full Text] [Related]
17. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas.
Chaux A; Albadine R; Schultz L; Hicks J; Carducci MA; Argani P; Allaf M; Netto GJ
Hum Pathol; 2013 Oct; 44(10):2323-30. PubMed ID: 23953228
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.
Hansel DE; Platt E; Orloff M; Harwalker J; Sethu S; Hicks JL; De Marzo A; Steinle RE; Hsi ED; Theodorescu D; Ching CB; Eng C
Am J Pathol; 2010 Jun; 176(6):3062-72. PubMed ID: 20395440
[TBL] [Abstract][Full Text] [Related]
20. Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostate.
Faraj SF; Albadine R; Chaux A; Gonzalez-Roibon N; Hicks J; Humphreys E; Partin A; Netto GJ
Urology; 2013 Nov; 82(5):1083-9. PubMed ID: 24035134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
